May 7, 2013
/PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announces that the Company's miRview
suite of oncology diagnostic assays will be highlighted in an "Industry Expert Theater Presentation" at the American Society of Clinical Oncologists (ASCO) 2013 Annual Meeting taking place from
May 31-June 4
at McCormick Place Convention Center in Chicago. The "Industry Expert Theater Presentation" is a series of hour-long presentations from industry leaders sharing the latest in oncology practices, products, services and technologies*.
Kenneth A. Berlin
, Rosetta Genomics' President and Chief Executive Officer, and
E. Robert Wassman
, MD, FAAP, FACMG, Rosetta Genomics' Chief Medical Officer, will deliver a presentation entitled, "Application of microRNAs in Oncology Diagnostics," on
Saturday, June 1
in the Oncology Professionals Hall.
"We are delighted to have secured a session in this prestigious program. This is an exceptional opportunity for us to showcase Rosetta's cutting edge, microRNA-based oncology diagnostic assays before an audience of influential oncologists who are seeking to learn about the latest products and technologies that will assist them in optimizing treatment protocols for their patients," said Mr. Berlin.
"Developments in targeted cancer therapies are driving the need for more accurate classification of tumor types, which help to guide treatment decisions. Our microRNA technologies, with their high reproducibility, robustness, and accuracy are well suited to provide valuable clinical information to predict and diagnose cancer, and therefore, help to optimize treatment," added Dr. Wassman.
assays are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test, miRview
mets², accurately identifies the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). miRview
meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview
lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview
kidney accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. miRview
assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview
mets² assay, 60,000 from miRview
meso, 65,000 from miRview
kidney and 226,000 patients from miRview
lung. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit
. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.